Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L
Department II, Medical Clinic, University of Tübingen, Germany.
Br J Haematol. 2000 Jan;108(1):93-5. doi: 10.1046/j.1365-2141.2000.01825.x.
We treated 21 elderly patients with high-risk myelodysplasia (n = 14) or secondary acute myeloid leukaemia (n = 7) with 2 mg of melphalan orally once a day until a complete peripheral response was obtained or until there was evidence of treatment failure. We observed seven (30%) complete and two (10%) partial peripheral responses occurring within 4-16 weeks and lasting for 12 + to 55 weeks. In relapse, retreatment was successful in most of the patients. Responses were associated with the absence of complex cytogenetic abnormalities and with a normal or reduced bone marrow cellularity.
我们对21例高危骨髓增生异常综合征患者（n = 14）或继发性急性髓系白血病患者（n = 7）进行治疗，口服美法仑2毫克，每日一次，直至获得完全外周反应或出现治疗失败的证据。我们观察到在4 - 16周内出现了7例（30%）完全外周反应和2例（10%）部分外周反应，持续时间为12 +至55周。复发时，大多数患者再次治疗成功。反应与无复杂细胞遗传学异常以及正常或降低的骨髓细胞密度有关。
